Please login to the form below
allergy
This page shows the latest allergy news and features for those working in and with pharma, biotech and healthcare.
Aimmune gets FDA panel backing for peanut allergy therapy
Step closer to becoming first approved treatment. Aimmune’s AR101 has moved a step closer to becoming the first approved peanut allergy treatment in the US after an FDA advisory committee ... Peanut allergies are the leading cause of death from
Latest news
-
ALK-Abello debuts its birch pollen allergy therapy in Germany
Birch trees are one of the most common causes of tree pollen allergy. ... Tree pollen allergy is one of the world’s major respiratory allergies,” commented Søren Niegel, ALK’s head of commercial operations.
-
DBV refiles peanut allergy immunotherapy in the US
Follows initial manufacturing concerns. DBV Technologies was hit hard a few months back when it was forced to pull its FDA filing for peanut allergy therapy Viaskin Peanut. ... The two are being held up as potential life-saving therapies for the
-
FDA clears Dupixent as first-ever drug for chronic rhinosinusitis with nasal polyps
Nasal polyps can lead to loss of smell and often patients require surgery to remove the polyps,” said the agency’s head of pulmonary, allergy and rheumatology products Sally Seymour. ... allergies and chronic obstructive pulmonary disease (COPD), a
-
Aimmune wins over ICER for peanut allergy product
for the 1.6m people with peanut allergy in the US, and presented its case at an ICER meeting yesterday. ... Analysts at GlobalData have suggested the market for peanut allergy products in eight major word markets could be worth $4.5bn in 2027.
-
GSK’s Nucala gets boost with self-administration approval
Tonya Winders, president, Global Allergy and Asthma Patient Platform (GAAPP), added: “People living with conditions like severe asthma often struggle to control their day-to-day symptoms, making routine activities like
More from news
Approximately 15 fully matching, plus 182 partially matching documents found.
Latest Intelligence
-
Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019
Forecast sales for Skyrizi in 2023 are $1.74bn. AR-101 from Aimmune Therapeutics addresses peanut allergy.
-
Drug launches to watch in 2019
conditions. 2. AR101 – the first peanut allergy treatment. Potentially deadly allergies to food and other everyday substances are on the rise around the world – and there are currently very few therapies ... There are more than 1.5 million peanut
-
Asthma: beyond the blue and the brown
for prevention of cat and ragweed allergies.
-
Deal Watch July 2016
And Finally, Reality Bites. ALK-Abello has issued a press release announcing that Merck &Co has walked away from the deal agreed in 2007 (with Schering-Plough) for the allergy treatments ... Grastek and Ragwitek are sublingual allergy immunotherapy (SLIT)
-
Allergies and asthma
The safest way to manage allergy symptoms is to tackle them before they set in. ... of the hypo-allergenic milk formula on cow's milk allergy and atopic dermatitis (AD).
More from intelligence
Approximately 1 fully matching, plus 18 partially matching documents found.
Latest appointments
-
ALK-Abello appoints Søren Jelert as CFO
He will be based at the company’s headquarters in Denmark. Dansih allergy immunotherapy company ALK-Abello has appointed Søren Jelert as its new chief financial officer, a role that sees ... to become a truly global allergy company.”.
-
Cytovation expands management team
Grego is currently chief executive officer of Spire Bioventures, a global healthcare consultancy and mentoring service, and has previously held a number of management positions at Spanish allergy specialist Laboratorios LETI.
-
Lars Dreiøe joins Sobi in senior quality and compliance role
He will join the firm in January from Danish allergy vaccine company ALK Abelló, where he was international head of quality.
-
ARC names chairman and member of the board
ARC is a privately held biopharma company developing desensitisation treatments for food allergies. ... Iwicki said: “ARC is working to address a very compelling therapeutic area and provide an option to those dealing with food allergies.
-
Insmed appoints FDA's Dr Eugene Sullivan
He also spent a seven-year spell from 1999 at the FDA, where he held several positions, including deputy director of its Pulmonary and Allergy Products division.
More from appointments
Approximately 0 fully matching, plus 14 partially matching documents found.
Latest from PMHub
-
Corporate event food. How to get it right
Vegetarian. Vegan. Gluten-free. Peanut allergies. Lactose intolerant. Diabetic. Kosher. Halal. To keep everyone happy, be sure to ask your delegates if they have any dietary requirements ASAP.
-
Blog: The Future of Food Allergy? The Emergence of Targeted Allergy Treatments
Research Analyst Rachel Arthurs explores how public exposure to the complications of food allergy has affected attitudes toward treatment. ... This is not an isolated incident, but a constant fear and source of anxiety for allergy sufferers all over the
-
Atopic Dermatitis — Going Beyond the Pill
The majority of patients start to experience symptoms before they reach 5 years of age and often suffer from asthma or other allergies.
-
Barber shops provide a short cut to BP reduction
Allergy testing in flower shops? Why not? All it requires is localised expertise, and a government that is keen to devolve the complexity and cost of healthcare, which the NHS is
-
IGNIFI
cardiovascular disease. diabetes. women’s health. nutrition. allergy. infectious diseases. wound care.
More from PMHub
Approximately 3 fully matching, plus 11 partially matching documents found.
Featured jobs
- Senior Medical Writer – Medical Communications – North West – In...
-
Excellent Remuneration Package
-
Senior Copywriter
-
Salary TBC
- Senior Account Manager / Account Director - MedComms - London
-
Highly competitive salary &package
-
Senior Medical Writer
-
Salary TBC
- Experienced / Senior Medical Writer - Excellent Progression Oppo...
-
Excellent Salary and Benefits on offer
-
Account Director, Medical Education
-
Salary TBC
- Account Director, Healthcare Communications Agency
-
£54, 000- £60, 000
- Senior / Principal Medical Writers wanted - MedComms - Various U...
-
Excellent Remuneration Packages
- Editorial Assistants - Medical Communications agency - Cheshire
-
Excellent Remuneration Package
-
Events Executive
-
DOE
-
Senior Medical Writer
-
Competitive salary plus benefits
Subscribe to our email news alerts
- Novartis bags US okay for Lucentis follow-up Beovu in wet AMD
- GSK forms cell therapy R&D pact with star-studded biotech
- UCB gets bigger in rare diseases with $2.1bn purchase of Ra Pharma
- J&J hit by $8bn judgment for man claiming breast growth due to Risperdal
- Gilead builds case for Xeljanz rival filgotinib as it preps US filing
- PMLiVE launches its inaugural T40
- Horizon shares data on eye disease drug as FDA decision nears
- Tranexamic acid linked to lower death rate in some brain injury patients
- Allergan investors back AbbVie deal, but is a tax charge looming?
- Bayer/J&J claim new FDA okay for clot drug Xarelto
- PANDAS/PANS Awareness: A parent’s story
- Leading AstraZeneca’s return to growth in Europe
PMHub
Real Science Communications
Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...
Latest intelligence
- PANDAS/PANS Awareness: A parent’s story
- To help raise awareness of these often underdiagnosed diseases, Jon Hallows, Joint MD at Porterhouse shares his own experience as a parent of a son recently diagnosed with PANDAS...
- Leading AstraZeneca’s return to growth in Europe
- PME talks to Iskra Reic, the company’s head of Europe and Canada...
- The era of digital wellbeing
- Social media - friend or foe?...
Quick links
Infographics
